BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  BioSpace Movers & Shakers: Altos Labs, Vektor, Nautilus, Nurix & More

  New chief executive officers take the reins of companies, while chief financial officers step into their roles overseeing the finances of respective businesses and more.

  August 4, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  U.S. Regulators Announce Plans for Monkeypox Antiviral Trial

  Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.

  August 4, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Horizon, Eli Lilly, Gilead & More Hit Financial Speed Bumps in Q2

  Horizon Therapeutics, Eli Lilly, Gilead Sciences and more hit financial road bumps or missed the mark entirely in their Q2 earnings reports.

  August 4, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Eli Lilly Q2: Down 4% as Government Pushes on Insulin Prices, Forced to Pay $61 Million Fine

  The big hit has been for its insulin Lispro products. Since January 1, Lispro and Humalog have dropped 26% to $447.1 million in the first quarter.

  August 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Zymeworks CSO Paul Moore Tasked with Shepherding Pipeline at Critical Juncture

  Paul Moore took over as CSO at Zymeworks in July at a pivotal time for the company. He spoke with BioSpace about his ambitions.

  August 4, 2022

   · 

  5 min read

   · 

  Abbey Glasure
• 

  Drug Development

  Pfizer Cancels Phase III Drug Trial for Cardiovascular Disease

  Lackluster initial results forces Pfizer to discontinue Phase III trial on a potential drug for symptomatic dilated cardiomyopathy (DCM).

  August 4, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Amgen’s Emerging Pipeline: Two BiTE Molecules Gone, ChemoCentryx Buy (Updated)

  In its Q2 earnings report, Amgen revealed the demise of two HLE BiTE molecules. Also on Thursday, the company announced it is acquiring ChemoCentryx for $4 billion.

  August 4, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Research Roundup: Why Kids Have More Protection Against COVID-19 & More

  Covid-19, aging, stroke, ALS, colorectal cancers and Alzheimer’s disease are all the focus of this week’s top research stories.

  August 4, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Two New Triggers for Alzheimer’s Identified: What Does it Mean?

  Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer’s disease.

  August 4, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Policy

  Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy

  In its Q2 conference call, Sarepta Therapeutics indicated plans to accelerate its timeline for SRP-9001 a gene therapy for Duchenne muscular dystrophy (DMD).

  August 4, 2022

   · 

  4 min read

   · 

  Mark Terry